We focus on innovation. Our targeted therapies block a common pathway that can disrupt bacterial or viral infections as well as blood and stomach cancers with a single drug at a fixed dose. We can help more than 100 million patients worldwide with our products.


Inhibikase initiating a PML survivor study for markers of JCV infection

Inhibikase Therapeutics is initiating a study of patients who survived Progressive Multifocal Leukoencephalopathy (PML).  The goal of this study is to measure markers of infection by the causative virus of PML, known as JC virus (JCV).If your disease was induced by either HIV/AIDS or while taking a medication for treatment of multiple sclerosis (MS), Inhibikase Therapeutics wants to hear from you. (Click here)

Click below for more information on products in or nearing clinical testing.